Cargando…
Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study
BACKGROUND: Performing well-powered randomised controlled trials (RCTs) of new treatments for rare diseases is often infeasible. However, with the increasing availability of historical data, incorporating existing information into trials with small sample sizes is appealing in order to increase the...
Autores principales: | Brard, Caroline, Hampson, Lisa V., Gaspar, Nathalie, Le Deley, Marie-Cécile, Le Teuff, Gwénaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480797/ https://www.ncbi.nlm.nih.gov/pubmed/31018832 http://dx.doi.org/10.1186/s12874-019-0714-z |
Ejemplares similares
-
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
por: Brard, Caroline, et al.
Publicado: (2019) -
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial
por: Varlet, Pascale, et al.
Publicado: (2020) -
Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine
por: Belhechmi, Shaima, et al.
Publicado: (2023) -
DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
por: Grill, Jacques, et al.
Publicado: (2020) -
A two-stage drop-the-losers design for time-to-event outcome using a historical control arm
por: Abbas, Rachid, et al.
Publicado: (2022)